Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes (Liratime)

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Novo Nordisk A/S
Information provided by (Responsible Party):
Peter Rossing, Steno Diabetes Center
ClinicalTrials.gov Identifier:
NCT01499108
First received: December 12, 2011
Last updated: November 27, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is enrolling participants by invitation only.
  Estimated Study Completion Date: August 2014
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)